Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils

Inflammation

Volumn 20, Issue 6, 1996, Pages 693-705

  Anderson, Ronald ^a   Theron, Annette J ^a   Feldman, Charles ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CALCIUM IONOPHORE; CLARITHROMYCIN; ERYTHROMYCIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LUCIGENIN; LYSOPHOSPHATIDYLCHOLINE; MACROLIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOLIPID; REAGENT; ROXITHROMYCIN; SCAVENGER; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR; ZYMOSAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CELL STIMULATION; CHEMOLUMINESCENCE; NEUTROPHIL; OPSONIZATION; PATHOGENESIS;

ADULT; ANTI-ASTHMATIC AGENTS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; AZITHROMYCIN; CALCIMYCIN; CELL MEMBRANE; CHEMILUMINESCENT MEASUREMENTS; CLARITHROMYCIN; ERYTHROMYCIN; HUMANS; IONOPHORES; LYSOPHOSPHATIDYLCHOLINES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PLATELET ACTIVATING FACTOR; RESPIRATORY BURST; ROXITHROMYCIN; SUPEROXIDES; TETRADECANOYLPHORBOL ACETATE; ZYMOSAN;

EID: 0030471653     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01488805     Document Type: Article

References (44)

1. ITKIN, I. H., and M. L. MENZEL. 1970. The use of macrolide antibiotic substances in the treatment of asthma. J. Allergy 45:146-162.
2. SPECTOR, S. L., F. H. KATZ, and R. S. FARR. 1974. Troleandomycin: effectiveness in steroid-dependent asthma and bronchitis. J. Allergy Clin. Immunol. 54:367-379.
3. SUEZ, D., and S. J. SZEFLER. 1986. Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion. J. Allergy Clin. Immunol. 77:330-334.
4. MIHATAKE, H., K. SUZUKI, F. TAKI, K. TAKAGI, and T. SATAKE. 1991. Effect of erythromycin on bronchial hyperresponsiveness in patients with bronchial asthma. Arzneim. Forsch. Drug Res. 41:552-556.
5. ROSENBERG, S. M., H. GERHAND, M. M. GRUNSTEIN, and C. M. SCHRAMM. 1991. Use of TAO with or without methylprednisolone in the treatment of severe asthma. Chest 100:849-850.
6. SHIMIZU, T., M. KATO, H. MOCHIZUKI, K. TOKUYAMA, K. MORIKAWA, and T. KUROUME. 1994. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 166:458-461.
7. GOSWAMI, S. K., S. KIVITY, and Z. MAROM. 1990. Erythromycin inhibits respiratory glyco-conjugate secretion from human airways in vitro. Am. Rev. Resp. Dis. 141:72-78.
8. TAMAOKI, J., K. ISONO, N. SAKAI, T. KANEMURA, and K. KONNO. 1992. Erythromycin inhibits C1 secretion across canine tracheal epithelial cells. Eur. Respir. J. 5:234-238.
9. TAKEYAMA, K., J. TAMAOKI, A. CHIYOTANI, E. TAGAYA, and K. KONNO. 1993. Effect of macrolide antibiotics on ciliary motility in rabbit airway epithlium in vitro. J. Pharm. Pharmacol. 45:756-758.
10. MIYACHI, Y., A. YOSHIOKA, S. IMAMURA, and Y. NIWA. 1986. Effect of antibiotics on the generation of reactive oxygen species. J. Invest. Dermatol. 86:449-453.
11. ANDERSON, R. 1989. Erythromycin and roxithromycin potentiate human neutrophil locomotion by inhibition of leukoattractant-activated superoxide generation and autooxidation. J. Infec. Dis. 159:966-973.
12. HIRATA, T., T. IZUMI, and S. OSHIMA. 1989. Inhibitory effect of erythromycin on the production of oxygen radical and chemotactic factor for neutrophils. Am. Rev. Resp. Dis. 139:A484.
13. LABRO, M. T., J. EL BENNA, and C. BABIN-CHEVAYE. 1989. Comparison of the in vitro effect of several macrolides on the oxidative burst of human neutrophils. J. Antimicrob. Chemother. 24:561-572.
14. HAND, W. L., D. L. HAND, and N. L. KING-THOMSON. 1990. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 34:863-870.
15. UMEKI, S. 1993. Anti-inflammatory action of erythromycin: its inhibitory effect on neutrophil NADPH-oxidase activity. Chest 104:1191-1193.
16. KONNO, S., M. ADACHI, K. ASANO, K. OKAMOTO, and T. TAKAHASHI, 1993. Anti-allergic activity of roxithromycin: inhibition of interleukin-5 production from mouse T lymphocytes. Life Sci. 52:PL25-30.
17. PETERS, D. H., H. A. FRIEDEL, and D. MCTAVISH. 1993. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44:750-799.
18. MINKENBERG, I., and E. FERBER. 1984. Lucigenin-dependent chemiluminescence as a new assay for NADPH-oxidase activity in particulate fractions of human polymorphonuclear leukocytes. J. Immunol. Meth. 71:61-67.
19. 2, but not protein kinase C, in the pro-oxidative interactions of clofazimine with human phagocytes. Biochem. Pharmacol. 37:4635-4641.
20. HOLMSEN, H. E., E. STORM, and H. J. DAY. 1972. Determinations of ATP and ADP in blood platelets: a modification of the firefly luciferase assay for plasma. Analyt. Biochem. 46:481-502.
21. NEU, H. C. 1991. The development of macrolides: clarithromycin in perspective. J. Antimicrob. Chemother. 27(Suppl A):1-9.
22. PURI, S. K., and H. B. LASSMAN. 1987. Roxithromycin: a pharmacokinetic review of a macrolide. J. Antimicrob. Chemother. 20(Suppl B):89-100.
23. ANDERSON, R., C. E. J. VAN RENSBURG, G. JOONE, and P. T. LUKEY. 1987. An in vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. J. Antimicrob. Chemother. 20(Suppl B): 57-68.
24. ANDERSON, R., G. JOONE, and C. E. J. VAN RENSBURG. 1988. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J. Antimicrob. Chemother. 22:923-933.
25. GLADUE, R. P., G. M. BRIGHT, R. E. ISAACSON, and M. F. NEWBORG. 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. 33:277-282.
26. ISHIGURO, M., H. KOGA, S. KOHNO, T. HAYASHI, K. YAMAGUCHI, and M. HIROTA. 1989. Penetration of macrolides into human polymorphonuclear leukocytes. J. Antimicrob. Chemother. 24:719-729.
27. RUBINEK, T., and R. LEVY. 1993. Arachidonic acid increases the activity of the assembled NADPH-oxidase in cytoplasmic membranes and endosomes. Biochim. Biophys. Acta. 1176:51-58.
28. 2 for activation of the assembled NADPH-oxidase in human neutrophils. Biochem. J. 297:217-223.
29. KUSNER, D. J., J. N. AUCOTT, D. FRANCESCHI, M. M. SARASUA, S. J. SPAGNUOLO, and C. H. KING. 1991. Protease priming of neutrophil superoxide production: effects on membrane lipid order and lateral mobility. J. Biol. Chem. 266:16465-16471.
30. WILES, M. E., J. A. DYKENS, and C. D. WRIGHT. 1994. Regulation of polymorphonuclear leukocyte membrane fluidity: effect of cytoskeletal modification. J. Leuk. Biol. 56:192-199.
31. ZIMMERMAN, G. A., S. M. PRESCOTT, and T. M. MCINTYRE. Platelet-activating factor: a fluid phase and cell-associated mediator of inflammation; In Inflammation: Basic Principles and Clinical Correlates. Gallin JI, Goldstein IM, Snyderman R, eds. New York; Raven Press Ltd. 149-176.
32. OISHI, K., R. L. RAYNOR, P. A. CHARP, and J. F. KUO. 1988. Regulation of protein kinase C by lysophospholipids. J. Biol. Chem. 263:6865-6871.
33. SAVAGE, J. E., A. J. THERON, and R. ANDERSON. 1993. Activation of neutrophil membrane-associated oxidative metabolism by ultraviolet radiation. J. Invest. Dermatol. 101:532-536.
34. ENGELBERGER, W., D. BITTER-SUERMANN, and U. HADDING. 1987. Influence of lysophospholipids and PAF on the oxidative burst. Internat. J. Immunopharmacol. 9:275-282.
35. GINSBURG, I., P. A. WARD, and J. VARANI. 1989. Lysophosphatides enhance superoxide responses of stimulated human neutrophils. Inflammation. 13:163-174.
36. PERRY, D. K., W. L. HAND, D. E. EDMONDSEN, and J. D. LAMBETH, 1992. Role of phospholipase D-derived diradylglycerol in the activation of the human neutrophil respiratory burst oxidase-inhibition by phosphatidic acid phosphohydrolase inhibitors. J. Immunol. 149:2749-2758.
37. AOSHIBA, K., A. NAYAI, and K. KONNO. 1995. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob. Agents Chemother. 39:872-877.
38. BARNES, P. J. 1989. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J. Allergy Clin. Immunol. 83:1013-1026.
39. 2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine. Am. Rev. Resp. Dis. 142:157-161.
40. MARQUARDT, D. L., and L. L. WALKER. 1991. Lysophosphatidycholine induces mast cell secretion and protein kinase C activition. J. Allergy. Clin. Immunol. 88:721-730.
41. GANBO, T., K. HISAMATSU, T. NAKAZAWA, A. KANJO, and Y. MURAKAMI. 1991. Platelet activating factor (PAF) effects on ciliary activity of human paranasal sinus mucosa in vitro. Rhinology. 29:231-237.
42. 4 in man. Eur. Respir. J. 4:551-560.
43. FELDMAN, C., R. ANDERSON, A. THERON, P. J. COLE, and R. WILSON. 1995. The effects of platelet activating factor (PAF) and lysophosphatidylcholine (LPC) on human ciliated epithelium in vitro. Am. J. Resp. Crit. Care Med. 151:A65.
44. HOVI, T., K. JOSEFESSON, and O. V. RENKONEN. 1983. Erythromycin absorption in healthy volunteers from single and multiple doses of enteric-coated pellets and tablets. Eur. J. Clin. Pharmacol. 25:719-729.